← Eichor
Study identifier: NCT06003036 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine

Condition: Schizophrenia · Schizoaffective Disorder  ·  Sponsor: Deepak K. Sarpal, M.D.

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to 50 Years
Healthy volunteersNo

About this study

In this study, the investigators will examine whether a type of repetitive transcranial magnetic stimulation called accelerated intermittent theta burst stimulation (iTBS) can augment neurocognition in individuals who receive treatment with clozapine. Following a baseline evaluation and magnetic resonance imaging (MRI), participants will undergo a session of iTBS +MRI and session of sham delivery + MRI. The order for these sessions will be blinded and randomized. The investigators predict that accelerated iTBS will enhance neurocognition relative to sham delivery.

This description comes directly from the study's public registry record.

Talk to the study team

Tori Blazinski  ·  412-246-5618  ·  blazinskit2@upmc.edu

Deepak Sarpal  ·  sarpaldk@upmc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

UPMC Western Psychiatric Hospital/University of PittsburghPittsburgh, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06003036